Novartis receives approval for Lucentis® and launches Galvus® in China
- Details
- Category: Novartis
Novartis received regulatory approval in China from the State Food and Drug Administration (SFDA) for Lucentis® (ranibizumab) to treat wet (neovascular) age-related macular degeneration (AMD), and is launching Galvus® (vildagliptin), an oral treatment for patients with type 2 diabetes approved in China as an add-on to metformin,
Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth
- Details
- Category: Nycomed
Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) announced today strategic measures to better align its global workforce and consolidate site operations in order to integrate legacy Nycomed operations,
Sanofi and Venture Capital Firms, Third Rock Ventures and Greylock Partners launched Warp Drive Bio
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) is co-investing in Warp Drive Bio, an innovative start-up biotechnology company, along with 2 venture capital firms, Third Rock Ventures (TRV), a venture capital firm based in Boston, Massachusetts, and Greylock Partners, a venture capital firm based in Menlo Park, California.
Medivation and Pfizer Announce Results from Phase 3 Concert Trial of Dimebon
- Details
- Category: Pfizer
Medivation, Inc. (NASDAQ: MDVN) and Pfizer Inc. (NYSE: PFE) today announced results from the CONCERT trial, which is a Phase 3 trial that evaluated dimebon (latrepirdine) when added to ongoing treatment with donepezil HCL tablets in patients with mild-to-moderate Alzheimer's disease.
Novartis to restructure US business to strengthen competitive position
- Details
- Category: Novartis
Novartis Pharmaceuticals plans to strengthen its long-term competitive position in anticipation of the Diovan® (valsartan) patent expiration and an expected reduction in demand for Rasilez®/Tekturna® (aliskiren) following termination of the ALTITUDE clinical study.
AstraZeneca and IMS Health announce real-world evidence collaboration in Europe
- Details
- Category: AstraZeneca
AstraZeneca has entered into a three-year collaboration agreement with IMS Health, the leading provider of information, services and technology for the healthcare sector, to advance the use of real-world evidence based on observational and retrospective studies throughout Europe to inform the delivery of effective and cost-efficient healthcare.
A New Resource That Offers Personalized Nutritional Guidance to Achieve Better Health
- Details
- Category: Pfizer
Millions of resolutions come with every New Year, many of which are to get healthy. But, there's a lot of confusion around what constitutes healthy nutrition, which is a key piece of the puzzle.
More Pharma News ...
- Bayer HealthCare to Share Lab Space with Start-Up Companies
- AstraZeneca reaffirms December 2011 financial guidance for 2011
- Bristol-Myers Squibb to Acquire Inhibitex
- Pfizer Receives FDA Approval to Extend Use of Prevnar 13®
- Boehringer Ingelheim significantly expands its supply center for China
- First-of-its-kind endovascular trial of the investigational Esprit(TM) therapy
- GlaxoSmithKline provides update on divestment of non-core over-the-counter (OTC) brands